Zepbound cut teens’ BMI by 18.5% in a big trial — and about half of them threw up
A Lilly-funded study in JAMA tested the weight-loss shot in 160 teens with obesity. The drug isn’t approved for anyone under 18.
Teenagers with obesity who took tirzepatide, the drug Eli Lilly sells as Zepbound for weight loss, lowered their body mass index (BMI) by 18.5% over 72 weeks, compared with a 0.5% rise for teens on a placebo, according to a study published Nov. 15 in JAMA. More than half of the teens on the drug, 54%, no longer met the definition of obesity by the end.
Side effects were common. About half of the teens on the drug vomited, and half had nausea. Zepbound is approved only for adults with obesity, and its label says its safety and effectiveness in children have not been established. Lilly has not announced plans to ask the Food and Drug Administration to approve it for teens.
How the drug works
Tirzepatide is a weekly shot that mimics two gut hormones, GLP-1 and GIP, which tell the brain the body is full and help control blood sugar. The same drug is sold as Mounjaro for type 2 diabetes. Four other obesity drugs are already approved for teens: orlistat, liraglutide, semaglutide and phentermine-topiramate.
What the trial found
The trial, called SURMOUNT-ADOLESCENTS, enrolled 160 teens ages 12 to 17 at 31 sites in six countries. It gave 109 of them the drug, at weekly doses of 5, 10 or 15 milligrams, and 51 a placebo, and all took part in a diet and exercise program. The share of teens who reached each level of BMI loss:
- At least 5%: 79.6% on the drug vs. 28.5% on placebo.
- At least 10%: 71.4% vs. 19.5%.
- At least 15%: 63.4% vs. 12.4%.
- At least 20%: 48.1% vs. 7.9%.
Lilly’s Nov. 14 announcement cited a 21.4% drop in BMI, a figure the company calculated a different way.
Side effects
Vomiting affected 50.9% of teens on the drug vs. 13.7% on placebo, and nausea affected 50.0% vs. 23.5%. Side effects led 9.3% of teens on the drug to stop, compared with none on placebo. Serious adverse events occurred in 7.4% vs. 3.9%.
Five teens on the drug (4.6%) and one on placebo reported depression or suicidal thoughts as side effects. None of those cases was serious, and all the teens who reported suicidal thoughts had a history of psychiatric problems, the researchers wrote.
Lilly paid for the study and helped design and analyze it. The researchers said longer follow-up is needed, the group of teens wasn’t very diverse, and many had already gone through puberty.